In the multiple biomarker study (TnI, CRP, GDF-15, MPO, PlGF, and sFlt-1) by Ky et al., only early increases in TnI and MPO levels were associated with subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. This evidence concerns the gene MPO and breast carcinoma.